Larvol Delta - iTeos-Therapeutics-to-Highlight-Inupadenant-Preclinical-Translational-and-Phase-2-A2A005-Clinical-Trial-Data-in-2L-NSCLC-at-ESMO-ImmunoOncology-Congress

inupadenant (EOS-850) - iTeos

https://www.globenewswire.com/en/news-release/2024/10/24/2968565/0/en/iTeos-Therapeutics-to-Highlight-Inupadenant-Preclinical-Translational-and-Phase-2-A2A-005-Clinical-Trial-Data-in-2L-NSCLC-at-ESMO-Immuno-Oncology-Congress.html

Oct 24, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next